BR112023024724A2 - Construtos de anticorpos multiespecíficos contra o muc1-c/domínio extracelular (muc1-c/ecd) - Google Patents

Construtos de anticorpos multiespecíficos contra o muc1-c/domínio extracelular (muc1-c/ecd)

Info

Publication number
BR112023024724A2
BR112023024724A2 BR112023024724A BR112023024724A BR112023024724A2 BR 112023024724 A2 BR112023024724 A2 BR 112023024724A2 BR 112023024724 A BR112023024724 A BR 112023024724A BR 112023024724 A BR112023024724 A BR 112023024724A BR 112023024724 A2 BR112023024724 A2 BR 112023024724A2
Authority
BR
Brazil
Prior art keywords
muc1
ecd
extracellular domain
antibody constructs
specific antibody
Prior art date
Application number
BR112023024724A
Other languages
English (en)
Inventor
W Kufe Donald
Govindaswamy Panchamoorthy
Surender Kharbanda
Original Assignee
Dana Farber Cancer Inst Inc
Xyone Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Xyone Therapeutics Inc filed Critical Dana Farber Cancer Inst Inc
Publication of BR112023024724A2 publication Critical patent/BR112023024724A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

construtos de anticorpos multiespecíficos contra o muc1-c/domínio extracelular (muc1-c/ecd). a presente invenção refere-se aos construtos de anticorpos multiespecíficos que se ligam a muc1-c/domínio extracelular (muc1-c/ecd) e a pelo menos um outro alvo de ligação. também são fornecidos métodos de utilização de tais construtos para tratar cânceres que expressam o antígeno muc1.
BR112023024724A 2021-05-28 2022-05-27 Construtos de anticorpos multiespecíficos contra o muc1-c/domínio extracelular (muc1-c/ecd) BR112023024724A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163194597P 2021-05-28 2021-05-28
PCT/US2022/031431 WO2022251695A2 (en) 2021-05-28 2022-05-27 Multi-specific antibody constructs against the muc1-c/extracellular domain ( muc1-c/ecd)

Publications (1)

Publication Number Publication Date
BR112023024724A2 true BR112023024724A2 (pt) 2024-02-15

Family

ID=84230363

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024724A BR112023024724A2 (pt) 2021-05-28 2022-05-27 Construtos de anticorpos multiespecíficos contra o muc1-c/domínio extracelular (muc1-c/ecd)

Country Status (9)

Country Link
EP (1) EP4346890A2 (pt)
JP (1) JP2024522116A (pt)
KR (1) KR20240021828A (pt)
CN (1) CN117769432A (pt)
AU (1) AU2022283436A1 (pt)
BR (1) BR112023024724A2 (pt)
CA (1) CA3220049A1 (pt)
IL (1) IL308881A (pt)
WO (1) WO2022251695A2 (pt)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
PL2274008T3 (pl) * 2008-03-27 2014-07-31 Zymogenetics Inc Kompozycje i sposoby hamowania PDGFRbeta i VEGF-A
CA2764180A1 (en) * 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
EP3327035A1 (en) * 2010-06-22 2018-05-30 Precision Biologics Inc. Colon and pancreas cancer specific antigens and antibodies
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
MX2016009954A (es) * 2014-01-29 2017-02-23 Dana Farber Cancer Inst Inc Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).
NZ761636A (en) * 2017-07-20 2023-07-28 Aptevo Res & Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
CA3082383A1 (en) * 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
KR20200139130A (ko) * 2018-03-27 2020-12-11 시스트이뮨, 인코포레이티드 유도 및 네비게이션 제어 단백질의 제조 및 사용 방법
EP3793600A4 (en) * 2018-05-16 2022-05-11 Arbele Limited COMPOSITION OF BISPECIFIC ANTIBODIES AND METHOD OF USE THEREOF
SG11202102178PA (en) * 2018-09-11 2021-04-29 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Improved anti-flt3 antigen binding proteins

Also Published As

Publication number Publication date
WO2022251695A2 (en) 2022-12-01
CN117769432A (zh) 2024-03-26
KR20240021828A (ko) 2024-02-19
CA3220049A1 (en) 2022-12-01
JP2024522116A (ja) 2024-06-11
AU2022283436A9 (en) 2023-12-07
EP4346890A2 (en) 2024-04-10
WO2022251695A3 (en) 2023-01-05
AU2022283436A1 (en) 2023-11-30
IL308881A (en) 2024-01-01
WO2022251695A8 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
MX2019011910A (es) Anticuerpos biespecificos de union especifica a pd1 y lag3.
CL2021000717A1 (es) Constructos de anticuerpo para cd70 y cd3. divisional de solicitud 270-2018
CY1119290T1 (el) Μονοκλωνα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου
WO2018151841A8 (en) Multispecific binding molecules having specificity to dystroglycan and laminin-2
MX2019012953A (es) Anticuerpo biespecifico contra ox40 y ctla-4.
CL2012002433A1 (es) Anticuerpo aislado o fragmento inmunoreactivo del mismo que comprende un dominio variable que se une específicamente a un dominio extracelular del receptor b7-h3; ácido nucleico que lo codifica; hibridoma que lo secreta; reactivo de redireccionamiento de doble afinidad (dart) que lo comprende; composición farmacéutica que lo comprende; y su uso para tratar cáncer.
CO2020014345A2 (es) Anticuerpos específicos para gucy2c y sus usos
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
EA201992038A1 (ru) Анти-псф-тау-антитела и способы их применения
BR112017019617A2 (pt) Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada
BR112012019887A2 (pt) camundongo da cadeia leve comum
PE20161096A1 (es) INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß)
BR112016003369A2 (pt) diacorpos monovalentes biespecíficos, diacorpos fc monovalentes biespecíficos, composição farmacêutica, uso da composição farmacêutica, célula que expressa uma cadeia de polipeptídeo de quaisquer dos diacorpos monovalentes biespecíficos, polinucleotídeo que codifica o polipeptídeo, e célula que expressa um anticorpo ou uma porção de polipeptídeo ou fragmento da mesma
BR112019000770A2 (pt) proteínas de ligação semelhantes a anticorpos biespecíficos que se ligam especificamente às cd3 e cd123
CO2021004560A2 (es) Anticuerpos estabilizadores de trem2
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
BR112022024221A2 (pt) Anticorpos para tigit
MX2021010893A (es) Anticuerpo biespecifico enlazado especificamente a vegf y ang2.
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA202190653A1 (ru) Конъюгаты связывающего белка с токсином, содержащие антрациклины, и их применение в иммуноонкологических целях
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
PE20221830A1 (es) Anticuerpos especificos contra la claudina 18.2 tumoral
CL2015001939A1 (es) Nuevos fragmentos de anticuerpos, composiciones y sus usos.
BR112023024724A2 (pt) Construtos de anticorpos multiespecíficos contra o muc1-c/domínio extracelular (muc1-c/ecd)
CO2024004055A2 (es) Polipéptidos